<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8003.26990 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 12/20/2021 8:52:53 PM -->
      <!-- iXBRL Library version: 1.0.8003.27000 -->
      <!-- iXBRL Service Job ID: 22a4146a-5623-4655-b137-8ecc574a2afa -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:kala="http://www.kalarx.com/20211216" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:EntityCentralIndexKey" id="Tc_9dAXCMEA-U-HGIJfkcil_w_2_1">0001479419</ix:nonNumeric><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:AmendmentFlag" id="Tc_6qHeG2qpIk-EVHietFgxfg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="kala-20211216.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479419</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-16</xbrli:startDate><xbrli:endDate>2021-12-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_561b7a00_00ca_4103_a05b_9d0e060b095b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b><b style="font-size:18pt;font-weight:bold;"><br /></b><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:DocumentType" id="Narr_1yDj2T9SgkaAd5_EzPOHlg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_1rVimAwhPE65B2F-3jZCGw"><b style="font-weight:bold;">December 16, 2021</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:EntityRegistrantName" id="Narr_w-hQRM0eJEKKQ1PNCglOTA"><b style="font-weight:bold;">Kala Pharmaceuticals,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(Exact Name of Company as Specified in its Charter)</p><a id="_a45f5a06_2c3a_4c99_9853_b3977d45b9f7"></a><a id="Tc_jcU9AtJOpUOd-UoXDfiGHQ_2_0"></a><a id="Tc_kPq2xid1C0yQWjLgBH8ypQ_2_1"></a><a id="Tc_fGiebgsMGUWkeP_Q6X2EGQ_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_Be1p0wG34E6S0Gfql18KNw_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:EntityFileNumber" id="Tc_6-CXhZJCnUafgS8aVvr4xg_1_1"><b style="font-weight:bold;">001-38150</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:EntityTaxIdentificationNumber" id="Tc_os4ZvGS1lECuS4De-PiGoQ_1_2"><b style="font-weight:bold;">27-0604595</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or Other Jurisdiction<br />of Incorporation)</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission<br />File Number)</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer<br />Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:EntityAddressAddressLine1" id="Narr_sRLcFwoC2Ei5eo_00d7L-g"><b style="font-weight:bold;">490 Arsenal Way</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:EntityAddressAddressLine2" id="Narr_kOmmMvtJe0WA_PPc2aY8fw"><b style="font-weight:bold;">Suite&#160;120</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:EntityAddressCityOrTown" id="Narr_ymo1Q39ULUa_qDrRRZ4-aQ"><b style="font-weight:bold;">Watertown</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:EntityAddressStateOrProvince" id="Narr_dfkdZV_qtkq94Cbm677DQw"><b style="font-weight:bold;">MA</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:EntityAddressPostalZipCode" id="Narr_TzLAnVBFDEKKdHq1Bpoouw"><b style="font-weight:bold;">02472</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(Address of Principal Executive Offices) (Zip Code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">Company&#8217;s telephone number, including area code: <b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:CityAreaCode" id="Narr_T5HzGb_aVkihUlFLEKgNhA"><b style="font-weight:bold;">781</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:LocalPhoneNumber" id="Narr_ASrFr5cVCkeFNcsZ4BDUTA"><b style="font-weight:bold;">996-5252</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p><a id="_b00eedb9_d838_4df4_9e3d_d66d4ff3bb22"></a><a id="Tc_uwqCU0Jq60K24UA5O27XeA_0_1"></a><a id="Tc_lwiU6-y0lEK2CDsVX3W7kg_2_1"></a><a id="Tc_Xu6BhdS9R0a3iftYuk7c3g_4_1"></a><a id="Tc_qGjvI7G_2EO0fXbVkDVx_w_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_R0VFan2bvEikYY36ZffiFA_0_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#00ff00;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_9p6-wKptb0O3cKB5rLDTDQ_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#00ff00;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_PrSDWHdZ4karqFzMvbLuzw_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#00ff00;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_Iog4au56JEWdcfuYstJQ_Q_6_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_8a391e05_e7fe_4f95_838a_86ac78c7bb53"></a><a id="Tc_ck9LvS84Q0aLsYy56rEKig_1_0"></a><a id="Tc_xsWj3Rq-a0W32m761uD_3g_1_1"></a><a id="Tc_6q0UWkRB40mb7pdYpselAg_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:17.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Trading symbol(s)</b></p></td><td style="vertical-align:bottom;width:40.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:Security12bTitle" id="Tc_tN0ozimORUSnV2b6TmYE2w_2_0">Common Stock, $0.001 par value per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:17.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" name="dei:TradingSymbol" id="Tc_ooEuarB4vkaT4HysKPdgpg_2_1">KALA</ix:nonNumeric></p></td><td style="vertical-align:top;width:40.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_OQaHVdnv7E6XB8GMgezohA_2_2">The Nasdaq Global Select Market</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.8pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.8pt;margin:0pt 0pt 6pt 0pt;">Emerging growth company&#160;<ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_v50o7csRo0W8dhJc5EX1Tw"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<ix:nonNumeric contextRef="Duration_12_16_2021_To_12_16_2021_H7aDKwFRQ06YsdWX_Fvytg" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_J0Hf0WC-T0eztdtSVyiczw"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_c1fa4f85_8fee_492c_92fa_87bcd62a638d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2021, the Board of Directors of Kala Pharmaceuticals, Inc. (the &#8220;Company&#8221;) appointed Todd Bazemore, the Company&#8217;s Chief Operating Officer, to serve as the Company&#8217;s President and Chief Operating Officer, effective immediately. Mark Iwicki will continue to lead the Company as its Chief Executive Officer and as Chairman of the Board of Directors but will no longer serve as President of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Bazemore, 51, has served as Chief Operating Officer of the Company since November&#160;2017. Previously, he served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA)&#160;Inc. (&#8220;Santhera&#8221;), a pharmaceutical company and subsidiary of Santhera Pharmaceuticals Holdings AG, from September&#160;2016 until November&#160;2017. Prior to joining Santhera, Mr.&#160;Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp. (&#8220;Dyax&#8221;), a biopharmaceutical company focused on orphan diseases, between April&#160;2014 and January&#160;2016, when Dyax was acquired by Shire&#160;plc. At Dyax, Mr.&#160;Bazemore oversaw all aspects of Dyax&#8217;s commercial department, including sales, marketing, commercial analytics, market access and patient services. Between April&#160;2012 and September&#160;2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals,&#160;Inc. (&#8220;Sunovion&#8221;) (a subsidiary of Dainippon Sumitomo Pharma Co.&#160;Ltd.), a global biopharmaceutical company focused on serious medical conditions. Prior to that, Mr.&#160;Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of the Respiratory Business Unit. Since October 2020, Mr. Bazemore has served on the board of directors of Pulmatrix Inc., a clinical stage publicly traded biopharmaceutical company. He received his Bachelor of Science from the University of Massachusetts, Lowell.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Mr. Bazemore has no family relationships with any of the Company&#8217;s directors or executive officers. There are no transactions and no proposed transactions between Mr. Bazemore and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There have been no changes to Mr. Bazemore&#8217;s compensatory plans or arrangements in connection with his appointment described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_af28f6eb_8f11_477e_8be8_26ac62ba50a3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:38.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">KALA PHARMACEUTICALS, INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: December 20, 2021</p></td><td style="vertical-align:bottom;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eric L. Trachtenberg</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:38.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eric L. Trachtenberg</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:38.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Counsel, Chief Compliance Officer and Corporate Secretary </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "kala-20211216x8k.htm", "description": "8-K", "secsgml_size_bytes": 32515}]
{"company-data": {"conformed-name": "Kala Pharmaceuticals, Inc.", "cik": "0001479419", "assigned-sic": "2834", "irs-number": "270604595", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-38150", "film-number": "211505268"}, "business-address": {"street1": "490 ARSENAL WAY", "street2": "SUITE 120", "city": "WATERTOWN", "state": "MA", "zip": "02472", "phone": "781-996-5252"}, "mail-address": {"street1": "490 ARSENAL WAY", "street2": "SUITE 120", "city": "WATERTOWN", "state": "MA", "zip": "02472"}}
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 16, 2021
Kala Pharmaceuticals, Inc.
(Exact Name of Company as Specified in its Charter)
​
​
​
Delaware
001-38150
27-0604595
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
​
490 Arsenal Way
,
Suite 120
Watertown
,
MA
02472
(Address of Principal Executive Offices) (Zip Code)
Company's telephone number, including area code:
(
781
)
996-5252
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​
​
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​
​
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​
​
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Securities registered pursuant to Section 12(b) of the Act:
​
​
​
Title of each class
Trading symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
KALA
The Nasdaq Global Select Market
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
​
​
​
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 16, 2021, the Board of Directors of Kala Pharmaceuticals, Inc. (the "Company") appointed Todd Bazemore, the Company's Chief Operating Officer, to serve as the Company's President and Chief Operating Officer, effective immediately. Mark Iwicki will continue to lead the Company as its Chief Executive Officer and as Chairman of the Board of Directors but will no longer serve as President of the Company.
Mr. Bazemore, 51, has served as Chief Operating Officer of the Company since November 2017. Previously, he served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA) Inc. ("Santhera"), a pharmaceutical company and subsidiary of Santhera Pharmaceuticals Holdings AG, from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp. ("Dyax"), a biopharmaceutical company focused on orphan diseases, between April 2014 and January 2016, when Dyax was acquired by Shire plc. At Dyax, Mr. Bazemore oversaw all aspects of Dyax's commercial department, including sales, marketing, commercial analytics, market access and patient services. Between April 2012 and September 2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc. ("Sunovion") (a subsidiary of Dainippon Sumitomo Pharma Co. Ltd.), a global biopharmaceutical company focused on serious medical conditions. Prior to that, Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of the Respiratory Business Unit. Since October 2020, Mr. Bazemore has served on the board of directors of Pulmatrix Inc., a clinical stage publicly traded biopharmaceutical company. He received his Bachelor of Science from the University of Massachusetts, Lowell.
Mr. Bazemore has no family relationships with any of the Company's directors or executive officers. There are no transactions and no proposed transactions between Mr. Bazemore and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.
There have been no changes to Mr. Bazemore's compensatory plans or arrangements in connection with his appointment described herein.
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
​
​
KALA PHARMACEUTICALS, INC.
​
​
Date: December 20, 2021
By:
/s/ Eric L. Trachtenberg
​
​
Name:
Eric L. Trachtenberg
​
​
Title:
General Counsel, Chief Compliance Officer and Corporate Secretary
​
​
​
​